Zika virus neutralizing antibody [Presence] in Specimen by Neutralization test
Qualitative result for Zika virus neutralizing antibodies in clinical specimens and isolates. Serological cross-reactivity is strong between Zika and other flaviviruses, especially Dengue virus. Therefore, positive EIA or IF assays are presumptive only and should be confirmed by a neutralization assay, such as the plaque-reduction neutralization test (PRNT), which can discriminate between Zika virus and cross-reacting antibodies in primary flavivirus infections.
Source: Regenstrief LOINC
LP200137-0 Zika virus
Zika virus (ZIKV) is a flavivirus transmitted primarily by the Aedes mosquito which was first identified in a sentinel monkey in the Zika forest in Uganda in 1947. Since 2014 it has spread explosively in the Americas where it has infected hundreds of thousands of people. About 80% of those infected are asymptomatic. Common symptoms include fever, headache, rash, arthralgia and conjunctivitis. Since the end of 2015, there has been an increase in ZIKV-associated cases of Guillain-Barre syndrome and a tremendous increase in cases of microcephaly in fetuses and newborns in Brazil, raising worldwide public health concern. Recent predictions are that the mosquito species A. Albopictus, which can hibernate and survive cool temperatures, will carry ZIKV to more temperate areas of North America, Australia and Southern Europe. It is still not clear whether ZIKV in humans increases viral titers enough to trigger a new cycle when an infected person is bitten by a naïve mosquito. Direct human-to-human transmission has been documented to occur perinatally, sexually (primarily through semen), through breastfeeding, blood transfusion and through occupational transmission in the laboratory setting. There are currently no specific anti-viral agents, vaccination or medical prophylaxis available. [PMID: 27148186] Source: Regenstrief LOINC
Neutralizing antibodies are antibodies that interfere with the interaction between the virus and its host cell receptor, therefore preventing infectivity. Neutralizing antibodies can be detected using a traditional VNT or other methods such as pseudovirus VNT and surrogate VNT. VNT and pseudovirus VNT use live virus (the actual virus or a recombinant virus that incorporates the viral antigen of interest, respectively) and cell culture to assess the virus-host interaction and whether neutralizing antibodies are present that block that interaction. Surrogate VNT (sVNT) does not use live virus but rather uses purified viral antigen and host cell receptor protein to mimic the same interaction. The sVNT method is currently (2021) represented in LOINC as IA, because it is an immunoassay-based method. Source: Regenstrief LOINC
In LOINC, the Method "Neut" represents the virus neutralization test (VNT), also called conventional VNT, which is a specific laboratory method that is used primarily for identifying whether neutralizing antibodies for the virus of interest are present in the patient sample. The VNT involves incubating patient serum with the virus of interest, and then inoculating onto cell culture. If neutralizing antibodies are present and the virus is neutralized, the cells will not be infected. If neutralizing antibodies are not present, the virus will infect the cells in the cell culture. [PMID: 32170698] This method can also be used to identify specific virus serotypes or strains, by performing separate tests in which serum is incubated with each of the specific virus serotypes or strains of interest. [PMID: 169804] Source: Regenstrief LOINC
- Zika virus Ab.Neut
- Short Name
- ZIKV NAb Spec Ql Nt
- Display Name
- ZIKV neut ab Neut test Ql (Specimen)
- Consumer Name Alpha
- Zika virus neutralizing antibody, Specimen
Example Answer List: LL2009-0Source: ARUP Laboratories
|PositiveCopyright http://snomed.info/sct ID:10828004 Positive (qualifier value)||LA6576-8|
|NegativeCopyright http://snomed.info/sct ID:260385009 Negative (qualifier value)||LA6577-6|
|EquivocalCopyright http://snomed.info/sct ID:42425007 Equivocal (qualifier value)||LA11885-3|
- First Released
- Version 2.61
- Last Updated
- Version 2.69
- Order vs. Observation
Member of these Groups
|LOINC Group||Group Name|
|zh-CN||Chinese (China)||寨卡病毒 抗体.中和:
|es-ES||Spanish (Spain)||Virus Zika Anticuerpos antineutrófilos:
|it-IT||Italian (Italy)||Zika virus Ab.Neut:
|fr-FR||French (France)||Zika virus Ac neutralisant:
|nl-NL||Dutch (Netherlands)||zikavirus As.neutraliserend:
|es-MX||Spanish (Mexico)||Ab.Neut del virus del Zika:
LOINC Terminology Service (API) using
Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.
- CodeSystem lookup
Third Party Copyright
This material includes SNOMED Clinical Terms® (SNOMED CT®) which is used by permission of the International Health Terminology Standards Development Organisation (IHTSDO) under license. All rights reserved. SNOMED CT® was originally created by The College of American Pathologists. "SNOMED" and "SNOMED CT" are registered trademarks of the IHTSDO.
This material includes content from the US Edition to SNOMED CT, which is developed and maintained by the U.S. National Library of Medicine and is available to authorized UMLS Metathesaurus Licensees from the UTS Downloads site at https://uts.nlm.nih.gov.
Use of SNOMED CT content is subject to the terms and conditions set forth in the SNOMED CT Affiliate License Agreement. It is the responsibility of those implementing this product to ensure they are appropriately licensed and for more information on the license, including how to register as an Affiliate Licensee, please refer to http://www.snomed.org/snomed-ct/get-snomed-ct or firstname.lastname@example.org<mailto:email@example.com>. This may incur a fee in SNOMED International non-Member countries.
Copyright © 2023 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright